الفهرس 
Introduction and aim of the work
Human plateletsOnly 14 pages are availabe for public view
 |  | from | 303 |  |  |
| | | from | 303 | | |
Abstract
Thrombocytopenia is a common problem among sick neonates, affecting 22 - 35% of all babies admitted to neonatal intensive care units . In most cases of neonatal thrombocytopenia, the etiology is unknown or multifactorial. Recent evidence suggests that in many sick newborns, the kinetic mechanism is reduced platelet production with a decreased megakaryocyte mass. Moreover, many other studies suggested that an inadequate elevation of thrombopoietin levels might complicate some cases of thrombocytopenia in preterm infants. In most of these thrombocytopenic neonates, the only available treatment is to repeatedly transfuse platelets exposing the newborn infants to many known risks, for example, viral infection, transfusion reactions, graft – versus-host disease and platelet refractoriness . On the other hand, morbidity among thrombocytopenic neonates, whether or not they received platelet transfusion is among the highest of any neonatal patient group encountered. The high incidence of thrombocytopenia in these patients and the poor outcome associated with this condition indicate that this is a serious health problem and suggest that alternate methods of treatment should for pursued. In addition, the published data on circulatory Tpo level among thrombocytopenic and non-thrombocytopenic newborns at different gestational ages till now are conflicting. The current study was conducted to measure thrombopoietin level during the first day of life in non-thrombocytopenic newborn at different gestational ages. In addition, we the measured thrombopoietin level in newborn infants presented with thrombocytopenia during the first week of life. Then follow up of these newborns till platelet resolution aiming to compare serum thrombopoietin level during thrombocytopenia and after its resolution.